Christina Mattina

Iptacopan targets one of the major proteins involved in the enzymes of the alternative pathway of complement, explains Carla Nester, MD, of Stead Family Children's Hospital.

John Mascarenhas, MD, discusses the rationale, mechanism, and design of the phase 1 INCA33989-101 and -102 trials investigating a CAL-R–targeted antibody for patients with essential thrombocythemia.

New data show sharp growth in pharmacists’ clinical roles, from the intensive care unit to outpatient chronic disease management, amid staffing and drug shortages.

In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.

Eric Lander, MD, discussed the difficulty that clinicians and pharmacists face in getting insurance coverage for category 2B treatments in the National Comprehensive Cancer Network guidelines, which could affect how patients are treated for cancer.

Belimumab is now the first and only subcutaneous biologic therapy approved for at-home administration in pediatric lupus nephritis.

The elimination of the program addressing LGBTQ+ individuals on the national suicide hotline makes reaching specialized help harder, says Hannah Wesolowski of the National Alliance on Mental Illness.

Rising grocery prices are forcing most Americans to shift toward ultraprocessed foods, leading to increased health risks and exacerbating existing disparities, particularly among underserved communities.

Lorna Warwick, CEO of the Lymphoma Coalition, highlights findings underscoring the vital role of clinician communication in managing adverse effects and supporting patient confidence in lymphoma and chronic lymphocytic leukemia (CLL) care.

Up to 257 million Americans could benefit from these prior authorization reforms that could have cross-market implications on health care plans administered through commercial insurers, Medicare Advantage, and Medicaid.

In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with Ken Cohen, MD, executive director of translational research at Optum Health.

Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia, breaks down how to communicate the value of dupilumab using patient-centered language and sports metaphors to patients.

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.

Sessions and posters at the 2025 European Hematology Association Congress evaluated the potential and real-world practices of using artificial intelligence (AI) to predict and improve outcomes for patients with hematological diseases.

New data shed light on the best strategies for managing patients who develop interstitial lung disease (ILD) while being treated with trastuzumab deruxtecan. City of Hope will host a virtual breast cancer forum to review key studies presented at ASCO.

The role that artificial intelligence (AI) and other technology can play in care delivery is growing, said Coral Omene, MD, PhD, of Rutgers Cancer Institute and RWJBarnabas Health.

The late-breaking abstracts presented on the last day of the 2025 European Hematology Association (EHA) Congress show “what a vibrant clinical specialty we’re in,” according to session cochair Brian Huntly, PhD.

At the European Hematology Association (EHA) 2025 Congress, Ashley Yocum, PhD, highlights how the Beat AML Master Trial advances safe, personalized treatment and expands targeted therapy options for patients with acute myeloid leukemia (AML).

Adolescent and young adult (AYA) patients with hematological diseases have unique needs that require a multidisciplinary strategy to ensure their mental and sexual well-being during and beyond treatment, clinicians and patients agreed.

Adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved overall survival in transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), according to Matthew Matasar, MD, of Rutgers Cancer institute.

Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.

Patients with relapsed/refractory (R/R) multiple myeloma and lower socioeconomic status reported significantly worse quality of life and a higher burden of symptoms, according to Francesco Sparano, MSc, of the GIMEMA Foundation.

Our knowledge of the effects of space and low gravity on blood cells, clotting, and anemia continues to expand, but further research is needed as commercial spaceflights are poised to grow in popularity.

A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.

Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.

Effective toxicity management in oncology requires pharmacists to document interventions clearly and collaborate closely with multidisciplinary teams, says David Awad, PharmD, BCOP.

Late-breaking data reveal durable improvements in joint, skin, and quality of life outcomes with deucravacitinib.

Andrew Kuykendall, MD, Moffitt Cancer Center, explains the goals of the VERIFY trial and why its data on rusfertide could have paradigm-changing implications for patients with polycythemia vera (PV) who currently rely on frequent phlebotomies for relief.

Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center, discusses the potential consequences of losing free health care screening coverage.

New research reveals mental health recovery post COVID-19 takes nearly 3 times longer than physical health, highlighting the need for targeted care strategies.